ArticleJACC. Case reports2025
Coronary Polyarteritis Nodosa: Clinical Dilemmas in Diagnosis and Management.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical conditionsA 43-year-old woman presented with multiple coronary vascular wall irregularities, triple-vessel segmental stenosis, coronary aneurysmal dilatation, and coronary collateral arteries. She was diagnosed with polyarteritis nodosa (PAN) with coronary involvement. KEY QUESTIONS: What is the approach of management for coronary PAN? What role does a multidisciplinary approach play in optimizing the management and outcomes of patients with coronary PAN? OUTCOMES: The patient was treated with aggressive immunotherapy, including high-dose corticosteroids, mycophenolate, and later rituximab, to control inflammation and prevent vascular damage. Antithrombotic therapy (clopidogrel and rivaroxaban) and cardiovascular risk factor management (statins, angiotensin-converting enzyme inhibitors, and smoking cessation) were initiated. Although coronary artery bypass graft was considered because of triple-vessel disease, it was deferred as the patient remained stable. Regular follow-up demonstrated symptomatic improvement. TAKE-HOME MESSAGES: Coronary PAN requires a multidisciplinary approach for diagnosis and management. Medical therapy often takes precedence, with surgical interventions reserved for selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.